GlassScriptPhysician profile
Francis P Mc Cormick
NPI 1427061654
$4,652.95
in general payments reported to CMS, 2019-2025
24 companies · $820 in 2025
The $820 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,427 · 2020: $108 · 2021: $361 · 2022: $492 · 2023: $735 · 2024: $710 · 2025: $820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,264.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apollo Endosurgery US INC | $1,110.42 | 2019 | |
| Abbvie INC. | $1,010.22 | 2019-2025 | |
| Janssen Biotech, INC. | $621.35 | 2022-2025 | Tremfya, Stelara, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $457.55 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $297.25 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $186.60 | 2020-2024 | Trulance, Xifaxan |
| Merck Sharp & Dohme LLC | $155.77 | 2021-2024 | Dificid, Zinplava |
| Lilly USA, LLC | $120.60 | 2024-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $112.06 | 2024-2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $92.01 | 2021-2025 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $62.01 | 2022-2023 | |
| Ironwood Pharmaceuticals, INC | $58.79 | 2020-2024 | Linzess |
| Celgene Corporation | $52.76 | 2021-2022 | |
| Ardelyx, INC. | $49.37 | 2025 | Ibsrela |
| Qol Medical, LLC | $47.80 | 2022-2025 | Sucraid |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $44.64 | 2025 | Rezdiffra |
| Genzyme Corporation | $42.19 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $32.42 | 2024 | Dupixent |
| Phathom Pharmaceuticals, INC. | $24.76 | 2024 | Voquezna |
| Allergan, INC. | $20.98 | 2019 | |
| Gilead Sciences, INC. | $20.10 | 2021 | |
| Celltrion USA INC. | $18.29 | 2025 | Vegzelma |
| Braintree Laboratories, INC. | $15.01 | 2024 | Sutab, Suflave |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$8,811.60 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francis Mc Cormick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.